Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated (VRTX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · VRTX · as of Sep 30, 2025
Ownership Breakdown
1,581
Institutional Holders
▼ 46 vs Q2
$90.75B
Total Inst. Value
▼ $16.45B vs Q2
253.81M
Shares Outstanding
freeFloat 99.69%
232.14M
13F Shares Held
▼ 8.74M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
VRTX largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
CAPITAL WORLD INVESTORS pharmaceutical preparations | 25.91M | 10.09% | 10.09% | $10.15T | Nov 13, 2025 | ▼ 2.82M |
VANGUARD GROUP INC pharmaceutical preparations | 24.22M | 9.43% | 9.43% | $9.48T | Nov 7, 2025 | ▲ 243.1K |
BLACKROCK, INC. pharmaceutical preparations | 22.25M | 8.67% | 8.67% | $8.72T | Nov 12, 2025 | ▲ 381.1K |
CAPITAL RESEARCH GLOBAL INVESTORS pharmaceutical preparations | 16.55M | 6.45% | 6.45% | $6.48T | Nov 13, 2025 | ▲ 445.0K |
STATE STREET CORP pharmaceutical preparations | 11.61M | 4.52% | 4.52% | $4.55T | Nov 14, 2025 | ▼ 169.2K |
JPMORGAN CHASE & CO pharmaceutical preparations | 6.43M | 2.51% | 2.51% | $2.52T | Nov 26, 2025 | ▲ 565.4K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 5.97M | 2.33% | 2.33% | $2.33T | Nov 12, 2025 | ▲ 45.0K |
WELLINGTON MANAGEMENT GROUP LLP pharmaceutical preparations | 4.77M | 1.86% | 1.86% | $1.87T | Nov 14, 2025 | ▼ 41.3K |
CAPITAL INTERNATIONAL INVESTORS pharmaceutical preparations | 4.69M | 1.83% | 1.83% | $1.84T | Nov 13, 2025 | ▲ 2.05M |
ALLIANCEBERNSTEIN L.P. pharmaceutical preparations | 4.52M | 1.76% | 1.76% | $1.77T | Nov 14, 2025 | ▲ 144.3K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
28
Increased
+7.63M shares0
New Positions
first time holders22
Decreased
−12.11M shares0
Sold Out
fully exitedNet shares change (top 50)
4.48M
+7.63M / −12.11M
Net new holders
+6
0 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
VRTX insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
19
Buy transactions
8
Sell transactions
2.38
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Bozic Carmen EVP and CMO | May 29, 2026 | Sale | 1,974 | $450.00 | $888.3K | 22.8K | Form 4 ↗ |
Bunnage Mark E. EVP, Chief Scientific Officer | May 15, 2026 | Sale | 33 | $453.45 | $15.0K | 7.3K | Form 4 ↗ |
Bozic Carmen EVP and CMO | May 15, 2026 | Sale | 1,354 | $453.45 | $614.0K | 24.7K | Form 4 ↗ |
Bozic Carmen EVP and CMO | May 12, 2026 | Sale | 6,988 | $450.00 | $3.14M | 26.1K | Form 4 ↗ |
Upadhyay Suketu director | May 1, 2026 | Award | 796 | — | — | 3.6K | Form 4 ↗ |
Upadhyay Suketu director | May 1, 2026 | Award | 2,866 | $424.45 | $1.22M | 2.9K | Form 4 ↗ |
Upadhyay Suketu director | May 1, 2026 | D-Return | 796 | — | — | 1.6K | Form 4 ↗ |
Thornberry Nancy director | May 1, 2026 | Award | 472 | — | — | 2.5K | Form 4 ↗ |
Thornberry Nancy director | May 1, 2026 | D-Return | 398 | — | — | 2.1K | Form 4 ↗ |
Thornberry Nancy director | May 1, 2026 | Award | 1,433 | $424.45 | $608.2K | 1.4K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Vertex Pharmaceuticals Incorporated (VRTX) is primarily owned by institutional investors, who hold approximately 91.5% of total shares outstanding. Company insiders own approximately 0.31%, while retail and public investors account for the remaining 8.23%.
The largest institutional shareholder of Vertex Pharmaceuticals Incorporated is CAPITAL WORLD INVESTORS, holding approximately 25.91 million shares — equal to 10.09% of outstanding shares — as of September 30, 2025.
A total of 1,581 institutional investors currently hold VRTX stock, with a combined institutional value of approximately $90.75 billion as of the most recent 13F filing period.
Frequently asked questions
VRTX ownershipVertex Pharmaceuticals Incorporated (VRTX) is primarily owned by institutional investors, who hold approximately 91.5% of shares. The largest shareholder is CAPITAL WORLD INVESTORS with a 10.09% stake. Company insiders hold 0.31%. Data sourced from SEC Form 13F as of September 30, 2025.